OUR PIPELINE
Advancing Innovation, Transforming Lives
Our pipeline features groundbreaking therapies in development to address PTSD and other neuropsychiatric disorders. Each program reflects our commitment to advancing science and transforming patient care.
OUR PROGRAMS
BNC210: α7 Nicotinic Acetylcholine Receptor Negative Allosteric Modulator (NAM)
BNC210, a novel negative allosteric modulator of the α7 nicotinic acetylcholine receptor, targets glutamatergic hyperactivity in brain regions linked to stress, anxiety, and mood disorders, such as the amygdala and prefrontal cortex. Preclinical studies show anti-anxiety, anti-stress, and antidepressant effects, along with improved fear extinction, highlighting its potential for PTSD treatment.
INDICATIONS
Post-Traumatic Stress Disorder (PTSD)
PTSD is a chronic condition triggered by severe trauma, including combat, childhood abuse, or sexual violence. It manifests as intrusive memories, nightmares, severe anxiety, hypervigilance, depression, and emotional withdrawal, severely impacting daily life and well-being.
Clinical Trials Update
- Phase 2b ATTUNE Trial (completed September 2023): Conducted across 34 sites in the U.S. and U.K., the trial showed significant symptom reduction in PTSD patients. Effects were observed as early as Week 4, sustained through Week 12, with a notable effect size of 0.40. BNC210 demonstrated the potential for rapid and lasting relief.
Learn More
- View Attune Results scientific study published in NEJM Evidence
- For clinical trial details, visit clinicaltrials.gov.
INDICATIONS
Future Indications
Panic Disorder:
- In a Phase 1b study, BNC210 showed anti-panic properties by reducing both the number and intensity of panic attacks in a human model of panic disorder.
Generalized Anxiety Disorder (GAD):
- In a Phase 2 study, BNC210 demonstrated promising anti-anxiety effects, reducing anxiety scores (STAI) and improving threat avoidance behaviors. Functional MRI scans revealed a reduction in amygdala hyperactivity, a brain region linked to heightened anxiety.
OUR PROGRAMS
Partnered Programs
BNC210, a novel negative allosteric modulator of the α7 nicotinic acetylcholine receptor, targets glutamatergic hyperactivity in brain regions linked to stress, anxiety, and mood disorders, such as the amygdala and prefrontal cortex. Preclinical studies show anti-anxiety, anti-stress, and antidepressant effects, along with improved fear extinction, highlighting its potential for PTSD treatment.
PARTNERSHIP WITH MERCK
α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)
In 2014, Neuphoria partnered with Merck through an exclusive Research Collaboration and License Agreement to develop α7 Receptor PAMs for treating cognitive dysfunction in Alzheimer’s disease and other CNS disorders.
BNC375: The original lead molecule demonstrated robust, dose-dependent efficacy across multiple cognitive animal models.
MK-1167: Merck’s novel clinical candidate has shown improved drug-like and pharmacological properties in preclinical studies compared to BNC375.
PARTNERSHIP WITH CARINA BIOSCIENCES
LGR5 mAb For Solid Tumors (Legacy Oncology Program)
We advanced our oncology program, BNC101, targeting cancer stem cells, through external funding and out-licensing to create shareholder value. BNC101, a humanized monoclonal antibody targeting LGR5, a receptor overexpressed in solid tumors, was exclusively licensed to Carina Biotech in November 2020 for CAR-T therapy development.
Carina’s LGR5-targeted CAR-T therapy, CNA3103, is in Phase 1/2a trials for metastatic colorectal cancer, with patient dosing beginning in December 2023. Under the agreement, Bionomics may earn up to AUS$118 million in milestone payments plus royalties.
Contact us today
Discover how our groundbreaking technology is transforming mental health—contact us today to learn more.